The observed negative effects of both isoform-specific HIF-1α and HIF-2α ASO treatment on HCC tumorigenesis in our DEN-induced HCC mouse model, discourage the use of HIF-1α and HIF-2α as targets for the treatment of HCC. This evidence concerns the gene HIF1A and hepatocellular carcinoma.